Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Outcomes-Based Contracts May Be Negotiated By Michigan Medicaid

Executive Summary

Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.

You may also be interested in...

Colorado Medicaid Outcomes-Based Contracting Gets Green Light From CMS

State is third to obtain approval from CMS to negotiate supplemental rebates as part of value-based contract. Arrangements would be exempt from “best price” requirements.

California Dreaming: Long-Term Messages From Governor’s Rx Price Actions

Immediate impact of California Governor Newsom’s directive on drug pricing unlikely to be dramatic, but there are important long-term messages for biopharma companies to weigh.

Oklahoma Medicaid Plan For Value-Based Contracts Cleared By CMS

Agency approves "first ever" supplemental rebate plan to enable value-based contracting a US state Medicaid program.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts